COREVALVE EVOLUT R
Device
Medtronic, Inc.
Total Payments
$43.3M
Transactions
94,331
Doctors
10,131
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2024 | $15.1M | 32,683 | 5,385 |
| 2023 | $14.1M | 32,335 | 5,286 |
| 2022 | $14.0M | 29,312 | 4,985 |
| 2021 | $100.82 | 1 | 1 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $22.4M | 6,023 | 51.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $11.3M | 4,541 | 26.1% |
| Travel and Lodging | $3.6M | 12,589 | 8.4% |
| Food and Beverage | $3.2M | 70,767 | 7.5% |
| Grant | $1.7M | 89 | 3.9% |
| Consulting Fee | $849,694 | 229 | 2.0% |
| Space rental or facility fees (teaching hospital only) | $153,154 | 60 | 0.4% |
| Education | $2,636 | 33 | 0.0% |
Payments by Type
Research
$22.4M
6,023 transactions
General
$20.9M
88,308 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| TAVR Low Risk | Medtronic, Inc. | $6.0M | 1 |
| SMART Trial | Medtronic, Inc. | $5.3M | 14 |
| EXPAND II | Medtronic, Inc. | $4.4M | 7 |
| Optimize Pro | Medtronic, Inc. | $3.3M | 9 |
| CoreValve SURTAVI | Medtronic, Inc. | $1.6M | 0 |
| Low Risk Bicuspid | Medtronic, Inc. | $1.3M | 0 |
| FORWARD PRO Study | Medtronic, Inc. | $156,234 | 0 |
| CoreValve EUS | Medtronic, Inc. | $132,847 | 3 |
| Investigator Sponsored Research | Medtronic, Inc. | $88,626 | 0 |
| Expand I | Medtronic, Inc. | $83,080 | 0 |
| RESTORE | Medtronic, Inc. | $30,538 | 11 |
| Evolut PRO China Study | Medtronic, Inc. | $1,117 | 0 |
| Evolut R FORWARD PMS | Medtronic, Inc. | $139.72 | 0 |
Top Doctors Receiving Payments for COREVALVE EVOLUT R
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | Norfolk, VA | $22.3M | 5,891 |
| , MD | Vascular Specialist | Phoenix, AZ | $2.0M | 828 |
| Guilherme Attizzani | Cardiovascular Disease | Cleveland, OH | $584,643 | 700 |
| , MD | Interventional Cardiology | Lemoyne, PA | $557,507 | 423 |
| , M.D | Cardiovascular Disease | Scranton, PA | $334,922 | 289 |
| , M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Thousand Oaks, CA | $329,159 | 382 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Houston, TX | $305,949 | 238 |
| , MD | Internal Medicine | Ann Arbor, MI | $304,865 | 543 |
| , MD | Cardiovascular Disease | Norfolk, VA | $298,751 | 333 |
| , M.D | Specialist | Winchester, VA | $281,622 | 378 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | New York, NY | $265,715 | 224 |
| , MD | Internal Medicine | Chambersburg, PA | $244,821 | 340 |
| , M.D | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Boulder, CO | $223,199 | 260 |
| , MD | Cardiovascular Disease | Bend, OR | $210,527 | 201 |
| , MD | Cardiovascular Disease | Columbus, OH | $206,929 | 546 |
| , M.D | Cardiovascular Disease | Manchester, NH | $197,747 | 288 |
| , MD | Thoracic Surgery (Cardiothoracic Vascular Surgery) | Kansas City, MO | $179,595 | 165 |
| , MD | Interventional Cardiology | Munster, IN | $166,690 | 295 |
| , MD | Internal Medicine | Ann Arbor, MI | $159,529 | 488 |
| , MD | Cardiovascular Disease | Virginia Beach, VA | $155,726 | 214 |
| , M.D | Cardiovascular Disease | Los Angeles, CA | $145,041 | 183 |
| , M.D | Interventional Cardiology | Wabash, IN | $141,615 | 75 |
| , M.D | Cardiovascular Disease | Webster, TX | $141,600 | 251 |
| , M.D | Surgery | Atlanta, GA | $135,682 | 151 |
| Toby Rogers | Cardiovascular Disease | Washington, DC | $133,858 | 186 |
Ad
Manufacturing Companies
- Medtronic, Inc. $43.3M
Product Information
- Type Device
- Total Payments $43.3M
- Total Doctors 10,131
- Transactions 94,331
About COREVALVE EVOLUT R
COREVALVE EVOLUT R is a device associated with $43.3M in payments to 10,131 healthcare providers, recorded across 94,331 transactions in the CMS Open Payments database. The primary manufacturer is Medtronic, Inc..
Payment data is available from 2021 to 2024. In 2024, $15.1M was paid across 32,683 transactions to 5,385 doctors.
The most common payment nature for COREVALVE EVOLUT R is "Unspecified" ($22.4M, 51.8% of total).
COREVALVE EVOLUT R is associated with 13 research studies, including "TAVR Low Risk" ($6.0M).